Several other research analysts have also issued reports on DBVT. ValuEngine raised shares of DBV TECHNOLOGIE/S from a hold rating to a buy rating in a research note on Thursday, August 1st. Goldman Sachs Group initiated coverage on shares of DBV TECHNOLOGIE/S in a research note on Monday, June 17th. They issued a buy rating and a $14.00 target price on the stock. Finally, Zacks Investment Research lowered shares of DBV TECHNOLOGIE/S from a buy rating to a hold rating in a research note on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company. DBV TECHNOLOGIE/S currently has a consensus rating of Hold and a consensus target price of $14.81.
Shares of NASDAQ DBVT opened at $8.98 on Thursday. The firm has a market capitalization of $528.97 million, a PE ratio of -2.65 and a beta of 1.82. The company has a current ratio of 3.34, a quick ratio of 3.30 and a debt-to-equity ratio of 0.01. DBV TECHNOLOGIE/S has a 1 year low of $3.60 and a 1 year high of $25.77. The firm’s 50-day moving average is $9.63 and its 200-day moving average is $8.78.
Several hedge funds and other institutional investors have recently modified their holdings of DBVT. Perceptive Advisors LLC raised its position in shares of DBV TECHNOLOGIE/S by 219.8% in the 2nd quarter. Perceptive Advisors LLC now owns 3,609,084 shares of the company’s stock valued at $29,666,000 after acquiring an additional 2,480,560 shares during the period. Boxer Capital LLC raised its position in shares of DBV TECHNOLOGIE/S by 26.2% in the 2nd quarter. Boxer Capital LLC now owns 5,300,000 shares of the company’s stock valued at $43,566,000 after acquiring an additional 1,100,000 shares during the period. Bailard Inc. acquired a new stake in shares of DBV TECHNOLOGIE/S in the 1st quarter valued at approximately $2,675,000. Point72 Asset Management L.P. acquired a new stake in shares of DBV TECHNOLOGIE/S in the 2nd quarter valued at approximately $1,411,000. Finally, First Midwest Bank Trust Division raised its position in shares of DBV TECHNOLOGIE/S by 14.5% in the 1st quarter. First Midwest Bank Trust Division now owns 1,131,884 shares of the company’s stock valued at $8,727,000 after acquiring an additional 142,993 shares during the period. 46.37% of the stock is currently owned by institutional investors.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Story: Average Daily Trade Volume Explained
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.